2 min read
Connect with Veristat at Bio International Convention 2026
June 22-25, 2026 – San Diego, CA
🌎 Bringing the Global Biopharma Community Together
We’re delighted to be attending...
1 min read
Precision and efficiency are key in the intricate world of CNS drug development. Veristat's recent collaboration with a clinical-stage biopharmaceutical company showcases an agile medical writing and project management approach, revolutionizing the traditional drug approval process.
The company, which is developing novel therapies for psychiatric and neurological conditions, engaged Veristat for our deep expertise in CNS clinical trials. Recognizing the challenges of high failure rates in CNS studies, Veristat's initial role in biostatistics and programming consulting expanded to include critical regulatory affairs and biometrics services.
Medical Writing and Project Management Solutions:
Veristat's involvement was pivotal in developing the Summary of Clinical Safety (SCS) for the client's first NDA submission. An aggressive 5.5-week timeline was met with a strategically developed workflow and comprehensive medical writing. Our expert team translated complex data into a scientifically rigorous summary, adhering to stringent regulatory requirements.
Three Pillars of Success:
Comprehensive Medical Writing: Leveraging experienced medical writers, Veristat turned intricate data into a coherent and regulatory-compliant SCS document.
Strategically Developed Timeline and Workflow: Breaking the SCS into manageable sections eased the client's review burden with a clear project plan and timeline.
Effective Governance and Communication: Regular meetings and transparent communication ensured alignment with client expectations and timely resolution of any challenges.
This approach significantly lightened the client's review load. Veristat delivered the SCS drafts ahead of schedule, allowing the client more time for a thorough review. The final phase involved collaborative on-site editing, enhancing the efficiency of the process. The result? The client successfully submitted their NDA a day ahead of schedule, a testament to Veristat's commitment to excellence.
Veristat's case study is a beacon for biopharma companies navigating the complexities of CNS drug development. This collaborative success story exemplifies how agile medical writing and meticulous project management can accelerate the path to drug approval.
Download our case study for a comprehensive understanding of Veristat's innovative approach.
